Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study

Danilo Cortozi Berton, Álvaro Huber Dos Santos, Ivo Bohn Jr, Rodrigo Quevedo de Lima, Vanderléia Breda, Paulo José Zimermann Teixeira, Danilo Cortozi Berton, Álvaro Huber Dos Santos, Ivo Bohn Jr, Rodrigo Quevedo de Lima, Vanderléia Breda, Paulo José Zimermann Teixeira

Abstract

Objective:: To compare a once-daily long-acting β2 agonist (indacaterol 150 µg) with a once-daily long-acting anticholinergic (tiotropium 5 µg) in terms of their effects on exercise endurance (limit of tolerance, Tlim) in patients with moderate COPD. Secondary endpoints were their effects on lung hyperinflation, exercise-related dyspnea, and daily-life dyspnea.

Methods:: This was a randomized, single-blind, crossover pilot study involving 20 patients (mean age, 60.9 ± 10.0 years; mean FEV1, 69 ± 7% of predicted). Spirometric parameters, Transition Dyspnea Index scores, Tlim, and exertional dyspnea were compared after three weeks of each treatment (with a one-week washout period between treatments).

Results:: Nineteen patients completed the study (one having been excluded because of COPD exacerbation). Improvement in Tlim from baseline tended to be greater after treatment with tiotropium than after treatment with indacaterol (96 ± 163 s vs. 8 ± 82 s; p = 0.06). Tlim significantly improved from baseline after treatment with tiotropium (having increased from 396 ± 319 s to 493 ± 347 s; p = 0.010) but not after treatment with indacaterol (having increased from 393 ± 246 to 401 ± 254 s; p = 0.678). There were no differences between the two treatments regarding improvements in Borg dyspnea scores and lung hyperinflation at "isotime" and peak exercise. There were also no significant differences between treatments regarding Transition Dyspnea Index scores (1.5 ± 2.1 vs. 0.9 ± 2.3; p = 0.39).

Conclusions:: In patients with moderate COPD, tiotropium tends to improve Tlim in comparison with indacaterol. No significant differences were observed between the two treatments regarding their effects on lung hyperinflation, exercise-related dyspnea, and daily-life dyspnea. Future studies, including a larger number of patients, are required in order to confirm our findings and explore mechanistic explanations. (ClinicalTrials.gov identifier: NCT01693003 [http://www.clinicaltrials.gov/]).

Objetivo:: Comparar um β2-agonista de longa duração administrado uma vez por dia (indacaterol 150 µg) a um anticolinérgico de longa duração administrado uma vez por dia (tiotrópio 5 µg) quanto a seus efeitos na resistência ao exercício (limite de tolerância, Tlim) em pacientes com DPOC moderada. Os desfechos secundários foram seus efeitos na hiperinsuflação pulmonar, na dispneia causada pelo exercício e na dispneia na vida diária.

Métodos:: Estudo piloto randomizado cruzado e simples cego com 20 pacientes (média de idade: 60,9 ± 10,0 anos; média do VEF1: 69 ± 7% do previsto). Parâmetros espirométricos, pontuação no Transition Dyspnea Index, Tlim e dispneia aos esforços foram comparados após três semanas de cada tratamento (com uma semana de intervalo entre os tratamentos).

Resultados:: Dezenove pacientes completaram o estudo - um foi excluído por causa de exacerbação da DPOC. A melhora no Tlim tendeu a ser maior com tiotrópio do que com indacaterol (96 ± 163 s vs. 8 ± 82 s; p = 0,06). Em comparação com os valores basais, o Tlim melhorou significativamente com tiotrópio (aumentando de 396 ± 319 s para 493 ± 347 s; p = 0,010), mas não com indacaterol (aumentando de 393 ± 246 para 401 ± 254 s; p = 0,678). Não houve diferença entre os tratamentos quanto à melhora na pontuação na escala de dispneia de Borg e na insuflação pulmonar no "isotempo" e no pico do exercício. Também não houve diferenças significativas entre os tratamentos quanto à pontuação no Transition Dyspnea Index (1,5 ± 2,1 vs. 0,9 ± 2,3; p = 0,39).

Conclusões:: Em pacientes com DPOC moderada, o tiotrópio tende a melhorar o Tlim em comparação com o indacaterol. Não houve diferenças significativas entre os tratamentos quanto a seus efeitos na insuflação pulmonar, na dispneia durante o exercício e na dispneia na vida diária. São necessários mais estudos, com um número maior de pacientes, para confirmar nossos achados e explorar explicações mecanicistas. (ClinicalTrials.gov identifier: NCT01693003 [http://www.clinicaltrials.gov/]).

Figures

Figure 1. Flowchart of the study design.…
Figure 1. Flowchart of the study design. incCPET: incremental cardiopulmonary exercise testing; crCPET: constant-rate cardiopulmonary exercise testing; BDI: Baseline Dyspnea Index; and TDI: Transition Dyspnea Index.
Figure 2.. Consolidated Standards of Reporting Trials…
Figure 2.. Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the study.
Figure 3. Individual values (dashed lines) and…
Figure 3. Individual values (dashed lines) and mean values (solid lines) of changes from baseline in the limit of tolerance (Tlim) during constant-rate cardiopulmonary exercise testing after three weeks of treatment with indacaterol (squares) or tiotropium (triangles). *p †p = 0.06 for between-treatment difference.

References

    1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi: 10.1164/rccm.201204-0596PP.
    1. Montes de Oca M, López Varela MV, Acuña A, Schiavi E, Rey MA, Jardim J. ALAT-2014 Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines questions and answers. Arch Bronconeumol. 2015;51(8):403–416. doi: 10.1016/j.arbres.2014.11.017.
    1. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ., Jr A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122(1):47–55. doi: 10.1378/chest.122.1.47.
    1. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399–404. doi: 10.1136/thorax.58.5.399.
    1. Briggs DD, Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18(6):397–404. doi: 10.1016/j.pupt.2005.02.013.
    1. Hodder R, Kesten S, Menjoge S, Viel K. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2007;2(2):157–167.
    1. Santus P, Centanni S, Verga M, Di Marco F, Matera MG, Cazzola M. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med. 2006;100(7):1277–1281. doi: 10.1016/j.rmed.2005.10.008.
    1. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26(2):214–222. doi: 10.1183/09031936.05.00140404.
    1. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting ß -agonists for stable COPD a systematic review. Chest. 2012;142(5):1104–1110. doi: 10.1378/chest.11-2252.
    1. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M. Indacaterol provides 24-hour bronchodilation in COPD a placebo-controlled blinded comparison with tiotropium. Respir Res. 2010;11:135–135. doi: 10.1186/1465-9921-11-135.
    1. . Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD. Bethesda: National Institutes of Health; 2015.
    1. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751–758. doi: 10.1378/chest.85.6.751.
    1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi: 10.1183/09031936.05.00034805.
    1. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522. doi: 10.1183/09031936.05.00035005.
    1. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–735. doi: 10.1183/09031936.05.00034905.
    1. Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007;33(4):397–406. doi: 10.1590/S1806-37132007000400008.
    1. Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir. 1982;18(3):419–425.
    1. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis. 1981;123(2):185–189.
    1. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–381. doi: 10.1249/00005768-198205000-00012.
    1. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180–184. doi: 10.1513/pats.200508-093DO.
    1. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255. doi: 10.1164/rccm.201310-1863PP.
    1. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105(7):1030–1036. doi: 10.1016/j.rmed.2011.03.014.
    1. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD. 2011;8(5):340–345. doi: 10.3109/15412555.2011.594464.
    1. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840. doi: 10.1183/09031936.04.00116004.
    1. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, O'Donnell D. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168–1178. doi: 10.1378/chest.128.3.1168.
    1. O'Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol (1985) 2006;101(4):1025–1035. doi: 10.1152/japplphysiol.01470.2005.
    1. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guérin JC, Le Merre C. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006;73(4):420–427. doi: 10.1159/000089655.
    1. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102(7):1033–1044. doi: 10.1016/j.rmed.2008.02.001.
    1. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797–803. doi: 10.1183/09031936.00191810.
    1. Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE) a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–533. doi: 10.1016/S2213-2600(13)70158-9.
    1. O'Donnell DE, Laveneziana P, Webb K, Neder JA. Chronic obstructive pulmonary disease clinical integrative physiology. Clin Chest Med. 2014;35(1):51–69. doi: 10.1016/j.ccm.2013.09.008.
    1. Trevethick M, Clarke N, Strawbridge M, Yeadon M. Inhaled muscarinic antagonists for COPD--does an anti-inflammatory mechanism really play a role. Curr Opin Pharmacol. 2009;9(3):250–255. doi: 10.1016/j.coph.2009.02.003.
    1. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Jr, Boushey HA, Deykin A. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519–526. doi: 10.1164/rccm.200509-1519OC.
    1. Umeda N, Yoshikawa T, Kanazawa H, Hirata K, Fujimoto S. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology. 2008;13(3):346–352. doi: 10.1111/j.1440-1843.2008.01259.x.
    1. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. doi: 10.1056/NEJMoa1303342.
    1. van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med. 2009;103(1):22–29. doi: 10.1016/j.rmed.2008.10.002.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa